Brokerages expect LeMaitre Vascular Inc (NASDAQ:LMAT) to report $26.18 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for LeMaitre Vascular’s earnings. The highest sales estimate is $26.32 million and the lowest is $26.10 million. LeMaitre Vascular posted sales of $24.82 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 5.5%. The company is scheduled to announce its next quarterly earnings results on Thursday, October 25th.
According to Zacks, analysts expect that LeMaitre Vascular will report full-year sales of $106.76 million for the current fiscal year, with estimates ranging from $106.40 million to $107.02 million. For the next fiscal year, analysts forecast that the company will post sales of $116.33 million, with estimates ranging from $114.80 million to $117.98 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover LeMaitre Vascular.
LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, July 26th. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($0.21). LeMaitre Vascular had a return on equity of 19.49% and a net margin of 21.09%. The company had revenue of $27.02 million for the quarter, compared to the consensus estimate of $27.09 million. During the same quarter in the previous year, the company posted $0.23 EPS. The business’s revenue was up 4.9% on a year-over-year basis.
LMAT has been the topic of several analyst reports. BidaskClub lowered LeMaitre Vascular from a “strong-buy” rating to a “buy” rating in a report on Friday, June 8th. Roth Capital initiated coverage on LeMaitre Vascular in a report on Friday, June 8th. They set a “buy” rating and a $38.00 target price on the stock. ValuEngine upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, June 15th. Lake Street Capital initiated coverage on LeMaitre Vascular in a report on Monday, June 25th. They set a “buy” rating and a $45.00 target price on the stock. Finally, Canaccord Genuity upped their target price on LeMaitre Vascular from $31.00 to $35.00 and gave the stock a “hold” rating in a report on Monday, July 9th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $38.14.
LMAT traded down $0.06 on Friday, hitting $36.64. 134,700 shares of the company were exchanged, compared to its average volume of 141,512. LeMaitre Vascular has a 12 month low of $28.23 and a 12 month high of $41.28. The firm has a market capitalization of $748.16 million, a PE ratio of 43.12, a PEG ratio of 2.42 and a beta of 0.63.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 6th. Shareholders of record on Wednesday, August 22nd were paid a $0.07 dividend. The ex-dividend date of this dividend was Tuesday, August 21st. This represents a $0.28 annualized dividend and a yield of 0.76%. LeMaitre Vascular’s dividend payout ratio is 32.56%.
In other LeMaitre Vascular news, CEO George W. Lemaitre sold 22,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 25th. The stock was sold at an average price of $37.26, for a total value of $819,720.00. Following the sale, the chief executive officer now owns 3,085,291 shares in the company, valued at $114,957,942.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Chairman George W. Lemaitre sold 39,820 shares of the company’s stock in a transaction that occurred on Friday, July 27th. The shares were sold at an average price of $37.34, for a total value of $1,486,878.80. Following the completion of the sale, the chairman now owns 3,085,291 shares in the company, valued at approximately $115,204,765.94. The disclosure for this sale can be found here. Insiders sold 97,506 shares of company stock worth $3,608,759 in the last 90 days. Corporate insiders own 20.30% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in LMAT. Epoch Investment Partners Inc. raised its stake in LeMaitre Vascular by 20.8% in the second quarter. Epoch Investment Partners Inc. now owns 932,093 shares of the medical instruments supplier’s stock valued at $31,207,000 after buying an additional 160,754 shares during the period. Citadel Advisors LLC raised its stake in LeMaitre Vascular by 2,304.4% in the second quarter. Citadel Advisors LLC now owns 159,798 shares of the medical instruments supplier’s stock valued at $5,350,000 after buying an additional 153,152 shares during the period. Conestoga Capital Advisors LLC raised its stake in LeMaitre Vascular by 8.9% in the second quarter. Conestoga Capital Advisors LLC now owns 1,392,591 shares of the medical instruments supplier’s stock valued at $46,624,000 after buying an additional 113,705 shares during the period. BlackRock Inc. raised its stake in LeMaitre Vascular by 4.0% in the second quarter. BlackRock Inc. now owns 2,425,454 shares of the medical instruments supplier’s stock valued at $81,202,000 after buying an additional 93,615 shares during the period. Finally, Janus Henderson Group PLC raised its stake in LeMaitre Vascular by 14.4% in the second quarter. Janus Henderson Group PLC now owns 691,670 shares of the medical instruments supplier’s stock valued at $23,157,000 after buying an additional 87,197 shares during the period. Hedge funds and other institutional investors own 79.75% of the company’s stock.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.